Table 3 Characteristics of the study population (n=1,096)
Factor/strata | n | % | ||
|---|---|---|---|---|
Female gender | 372 | 33.9% | ||
Non Italian nationality | 284 | 25.9% | ||
Risk group | Heterosexual | 421 | 38.4% | |
Homo/bisexual | 213 | 19.4% | ||
IDU | 199 | 18.2% | ||
Other/unknown | 263 | 24.0% | ||
CDC stage | A | 495 | 45.2% | |
B | 229 | 20.9% | ||
C | 372 | 33.9% | ||
HIV subtype | B | 284 | 25.9% | |
28_BF | 84 | 7.7% | ||
17_BF | 48 | 4.4% | ||
F1 | 27 | 2.5% | ||
Other | 48 | 4.4% | ||
Unknown | 557 | 50.8% | ||
First-line anti-HIV therapy (encoding i) | 2NRTI+1NNRTI | 227 | 20.7% | |
2NRTI+1PI | 214 | 19.5% | ||
2NRTI+1PI/r | 426 | 38.9% | ||
Other combination | 229 | 20.9% | ||
First-line anti-HIV therapy (encoding iv) | Truvada® + Sustiva® | 47 | 4.3% | |
Atripla® | 14 | 1.2% | ||
Reyataz® ± ritonavir + backbone | 22 | 2.0% | ||
Kaletra® + backbone | 389 | 35.5% | ||
Any other NRTI+NNRTI | 165 | 15.0% | ||
Any other NRTI+PI | 221 | 20.2% | ||
Any other NRTI+PI/r | 18 | 1.6% | ||
Other combinations | 220 | 20.1% | ||
Non-anti-HIV therapies (concomitant) | anti-TB | 140 | 12.8% | |
anti-PCP | 425 | 38.8% | ||
anti-HCV | 14 | 1.3% | ||
other antibiotics | 194 | 17.7% | ||
other drugs | 238 | 21.7% | ||
HBsAg | negative | 978 | 89.2% | |
positive | 56 | 5.1% | ||
unknown | 62 | 5.7% | ||
HCVAb | negative | 771 | 70.3% | |
positive | 247 | 22.5% | ||
unknown | 78 | 7.1% | ||
Discontinuation/switch for adverse events | 302 | 27.5% | ||
Discontinuation/switch for other causes | 618 | 56.4% | ||
Non-discontinued first-line anti-HIV therapies | 176 | 16.1% | ||
Years | 1988-1993 | 1994-1998 | 1999-2004 | 2005-2010 |
Discontinuation/switch for adverse events | 17 | 92 | 108 | 85 |
Patients starting a first-line ART | 88 | 229 | 349 | 430 |
PYFU | 282.06 | 350.26 | 724.36 | 504.58 |
Numerical markers | Median | IQR | ||
Calendar year | 2003 | 1998-2006 | ||
Days on first-line anti-HIV therapy | 379 | 131-855 | ||
Age (years) | 36 | 31-43 | ||
Years from the first HIV positive test | 0.5 | 0.1-3.4 | ||
HIV-RNA Log10 copies/mL | 4.8 | 4.7-5.2 | ||
CD4+ T cells/mm3 | 194 | 122-233 | ||